Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASCO: Adjuvant Breast Cancer Beckons for Merck/AZ’s Lynparza With OlympiA

Executive Summary

A decent 42% reduction in the risk of recurrence in high-risk early-stage BRCA mutated disease should open another new market for the leading PARP inhibitor. Data also hint at a survival benefit to come.

You may also be interested in...



AstraZeneca/Merck’s Lynparza Is First Adjuvant Option For BRCA-Positive Breast Cancer

One of two PARP inhibitors approved in breast cancer, Lynparza may have the adjuvant breast indication all to itself for a while. One analyst projects a $1.5bn revenue opportunity for the indication.

Lynparza On Track For Broad Frontline Use In Prostate Cancer

AstraZeneca and Merck & Co’s latest results put them far ahead of competitors in prostate cancer in reaching patient regardless of their mutational status.

Five Late-Breakers To Watch For At ASCO 2021

This year’s American Society of Clinical Oncology meeting is set to take place virtually from 4-8 June, and while many abstracts have now been released for this year’s conference, we take a sneak peek at what is still under wraps, with five of the key late-breaking presentations due to be presented at the plenary session, with input from Biomedtracker and Datamonitor Healthcare.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel